- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01610375
Telephone Follow-up After Treatment for Endometrial Cancer (TEACUP)
Telephone Follow-up After Treatment for Endometrial Cancer.
The aim of this study is to investigate the feasibility, safety and accuracy of a telephone follow-up for women previously treatment for endometrial cancer.
To achieve this aim, potentially eligible women attending the Queensland Centre for Gynaecological Cancer (QCGC) outpatient clinic for review following previous treatment for endometrial cancer will be recruited by this study. The study aims to recruit all new patients as well as all patients who return to QCGC for their follow-up and who had treatment within the previous 2 years.
The proposed project will involve generation of an evidence-based checklist of signs and symptoms of disease recurrence from a thorough literature review. The generated symptom checklist will be pilot tested and the refined symptom checklist will be used to follow study participants over a period of 12 months.
During the follow-up period, the basic standard of follow-up after primary treatment for endometrial cancer at the QCGC, Royal Brisbane and Women's Hospital (RBWH)will not be altered; however, the study participants will be interview via telephone 2 to 5 days prior to their scheduled review dates.
The main outcome measure will be the estimated recurrence rate as derived from the telephone assessment and this will be compared to the clinically detected recurrences as recorded in patients' medical files.
It is hypothesized, that the telephone follow-up will identify 90% of all recurrences correctly that are later confirmed during the clinical follow-up.
In addition to the main outcome, we will also assess patients' satisfaction with each of the follow-up programs, whether or not lifestyle behaviours were queried and support offered to improve wellbeing.
Study Overview
Detailed Description
The focus of the study is;
- To generate an evidence-based checklist of signs and symptoms of recurrence of endometrial cancer.
- To assess the sensitivity and specificity of a telephone follow-up compared to the current clinic-based follow-up in the detection of recurrence of endometrial cancer.
- To determine patients' satisfaction with the clinic and telephone follow-up.
- To assess patients' self reported well being (physical activity, smoking, diet, anxiety, depression and quality of life).
The proposed project will involve generation of an evidence-based checklist of signs and symptoms of recurrence. The generated symptom checklist will be used to follow study participants over a period of 12 months.
During the follow-up period, patients' routine clinic follow-up schedules will not be altered, however; the study participants will be interviewed via telephone 2 to 5 days prior to their scheduled clinic visits dates. The checklist of signs and symptoms generated by this study will form the basis for this interview.
In addition, we will also enquire about the participant's wellbeing and provide resources on physical activity, diet and other life style behaviours and supportive care when needed.
The data analysis will include determining:
i. Sensitivity- Proportion of those with the condition who have a positive test.
ii. Specificity-Proportion of those without the condition who have a negative test.
iii. Positive predictive value (PV+) - Proportion of those with a positive test who have the condition.
iv. Negative predictive value (PV-) - Proportion of those with a negative test who do not have the condition.
Overall accuracy of the symptom checklist compared to the clinic-based follow-up program will also be calculated.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Queensland
-
Herston, Queensland, Australia, 4029
- Royal Brisbane and Women's Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
To be eligible for this pilot study, the patient must;
- Have completed primary treatment for endometrial cancer
- Be recurrence-free
- In the first to third year after treatment
- Be able to read and understand English
- Must have access to a telephone and adequate hearing
- Participants must be willing to complete questionnaire on satisfaction with nurse and clinic follow-up
Exclusion Criteria:
- Patients with disease recurrent or relapse
- Patients with metastatic disease presentation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: Telephone Follow-up
Women previously treated for endometrial cancer will be recruited into one study group and continue to be followed per the current routine clinic follow-up.
However, an additional program (telephone follow-up) will be offered in parallel to the current clinic follow-up.
Outcomes obtained from the telephone follow-up will be compared with the current clinical assessment.
|
This is a non-randomised observational study to assess the value of a symptom checklist to detect recurrence in women with endometrial cancer.
Women will be telephoned using an evidence-based symptom checklist in parallel to the standard clinic-based follow-up.
The researcher will call the participants 2 to 5 days prior to their scheduled clinic review dates to enquire about the presence of symptoms which may be indicative of disease recurrence.
In addition, the researcher will also enquire about the participants' wellbeing and provide standard lifestyle resource on physical activity, diet and other lifestyle behaviours and supportive care when needed.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Sensitivity, specificity and overall accuracy of the telephone follow-up compared to clinic-based follow-up and patients' satisfaction.
Time Frame: 12 months
|
The proposed project will involve generation of an evidence-based checklist of signs and symptoms of recurrence from a thorough literature review.
The generated symptom checklist will be pilot tested and used in a one year prospective cohort study.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in lifestyle behaviours and quality of life overtime.
Time Frame: 12 months
|
The researcher will conduct a telephone interview and will enquire about the participant's wellbeing and provide resources on physical activity, quality of life, diet, anxiety and depression and supportive care when needed prior to each clinic visit.
|
12 months
|
Collaborators and Investigators
Investigators
- Study Chair: Andreas Obermair, MD FRANZCOG CGO, Queensland Center for Gynecological Cancer
- Study Director: Monika Janda, PhD, Queensland University of Technology
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- TEACUP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Endometrial Cancer
-
Ain Shams Maternity HospitalNot yet recruitingTreatment Endometrial Cancer
-
Radboud University Medical CenterMaastricht University Medical Center; Erasmus Medical Center; Catharina Ziekenhuis... and other collaboratorsRecruitingEndometrial Cancer Recurrent | Endometrial Cancer Stage III | Endometrial Cancer Stage IVNetherlands
-
Assistance Publique - Hôpitaux de ParisUniversité Montpellier; Ecole d'econmie de Paris (PSE)-Hospinnomics; Université...CompletedEndometrial Cancer Stage I | Endometrial Cancer Stage IIFrance
-
Mayo ClinicRecruitingEndometrial Carcinoma | Stage III Endometrial Cancer | Stage IV Endometrial Cancer | Endometrial High Grade Endometrioid Adenocarcinoma | Stage II Endometrial CancerUnited States
-
Batman Training and Research HospitalEskisehir Osmangazi UniversityCompletedGynecologic Cancer | Endometrial Cancer Stage
-
Jonsson Comprehensive Cancer CenterStemline Therapeutics, Inc.Not yet recruitingRecurrent Endometrial Carcinoma | Advanced Endometrial Carcinoma | Metastatic Endometrial Carcinoma | Stage III Endometrial Cancer | Stage IV Endometrial CancerUnited States
-
Novartis PharmaceuticalsCompletedAdvanced Endometrial CancerBelgium, France, Italy, Canada, Spain, Australia, Germany, United States, Japan, Brazil, Singapore, Russian Federation, Poland
-
Eli Lilly and CompanyGynecologic Oncology GroupCompletedNeoplasms | Urogenital Neoplasms | Neoplasms by Site | Uterine Neoplasms | Genital Neoplasms, Female | Endometrial Neoplasms | Endometrial Cancer | Endometrium Cancer | Cancer of Endometrium | Cancer of the Endometrium | Neoplasms, EndometrialUnited States
-
Rambam Health Care CampusCompletedSerous Papillary Endometrial CancerIsrael
-
Samsung Medical CenterRecruitingEndometrial Cancer Stage IKorea, Republic of
Clinical Trials on Telephone Follow-up
-
Aalborg University HospitalRecruiting
-
St. Justine's HospitalCompleted
-
Connolly Hospital BlanchardstownCompletedGeneral Surgery | Outpatients | Virtual Clinic | Text MessagingIreland
-
Union Hospital, Tongji Medical College, Huazhong...CompletedMucosal Melanoma | FDG PETChina
-
Zealand University HospitalEnrolling by invitationNon-Functional Pituitary AdenomaDenmark
-
Shanghai General Hospital, Shanghai Jiao Tong University...RecruitingPelvic Organ Prolapse (POP) | Stress Urinary Incontinence (SUI)China
-
Brandon UniversityRecruiting
-
University Hospital, ToulouseFondation de l'AvenirCompletedSwallowing DisordersFrance
-
Massachusetts General HospitalCompletedDeep Vein Thrombosis | Pulmonary EmbolismUnited States
-
University of Southern DenmarkUniversity Hospital, Gentofte, CopenhagenCompleted